Latest Conference Articles

In a scientific session at the American Thoracic Society (ATS) 2024 International Conference titled "An Inconvenient Truth: Health Disparities and Health Care Inequality in Respiratory Medicine," a number of experts discussed the various areas within the field that are impacted by disparities.

Monica Kraft, MD, ATSF, contributed to research on preexisting asthma and the influence it may have on the severity of long-term COVID-19 symptoms, with some patients with asthma experiencing worse respiratory symptoms but better physical functioning compared with patients without asthma.

Study authors shared late-breaking data in a session on clinical trial results in pulmonary medicine at the American Thoracic Society 2024 International Conference.

Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more suitable for some patients to be treated with ASV than CPAP due to its ability to automatically adjust pressure and potentially improve comfort.

In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.

New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.

Julie Linton, MD, FAAP, immediate past chair of the American Academy of Pediatrics (AAP) Council on Immigrant Child and Family Health, discussed disparities within health care services impacting immigrant populations in the United States.

Jan Hedner, MD, PhD, finds sulthiame improves sleep quality and reduces daytime sleepiness in patients with sleep-disordered breathing (SDB), offering a potential alternative to continuous positive airway pressure (CPAP) machines. This highlights the growing field of non-CPAP treatments, with personalized medicine being a key focus for future research.

During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, shares 3 key recommendations to improve the accuracy and quality of drug pricing data.

In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV) in opioid users with central sleep apnea (CSA).

Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul Frohna, MD, PhD, PharmD.

Fatima Rodriguez, MD, MPH, from Stanford University, and Matthew DeCamp, MD, PhD, from the University of Colorado, joined Michael Howell, MD, MPH, of Google, on the stage at ATS 2024 to discuss artificial intelligence (AI) in health care.

The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.

Debra Boyer, MD, MHPE, ATSF, chair of the American Thoracic Society (ATS) International Conference Committee, highlighted exciting keynote sessions on artificial intelligence in medicine, the history of intensive care units, and immigrant health care ahead of the ATS 2024 International Conference.

Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.

Session speakers at the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research share their favorite parts of the conference.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.

Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.

Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.

New therapies being developed are moving into earlier lines of therapy, with the idea that most patients with early-stage prostate cancer will progress and need additional therapy later.

Phaedra Corso, PhD, associate vice president for research, Indiana University, discusses the importance of cost-effectiveness analysis in determining the feasibility and impact of public health interventions.

A panel discussion highlighted a new pathway that allows Medicare to embrace new tools and pay for them while gathering the evidence needed to ensure the technology is safe and appropriate for an older population.

William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits and advancements of cost-effectiveness analysis to improve decision-making and efficiency.

The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.

A CMS official discusses a draft guidance on the second round of drug pricing negotiations amid uncertainties over the first round of talks under the Inflation Reduction Act (IRA).

Risk factors and prostate-specific antigen are both important when determining how to move forward with treatment, explained Angela Jia, MD, PhD, of University Hospitals and Case Western Reserve University School of Medicine.

Nancy Dreyer, PhD, MPH, FISE, chief scientific advisor to Picnic Health, shares some of the ways that direct-to-patient approaches have improved observational research.